French president Emmanuel Macron is joining several African leaders to kick off a planned one billion dollars project to accelerate the rollout of vaccines in Africa, after the coronavirus pandemic exposed gaping inequalities in access to them.

The launch of the African Vaccine Manufacturing Accelerator, which will provide financial incentives to vaccine manufacturers, offered a momentary break for Mr Macron from domestic political concerns as legislative elections loom on June 30 and July 7.

Many African leaders and advocacy groups say Africa was unfairly locked out of access to Covid-19 treatment tools, vaccines and testing equipment — that many richer countries bought up in huge quantities — after the pandemic swept the world starting in 2020.

The World Health Organisation, advocacy groups and others want to help Africa get better prepared for the next pandemic, which many health experts say is inevitable.

When the coronavirus pandemic began, South Africa was the only country in Africa with any ability to produce vaccines, officials say, and the continent produced a tiny fraction of all vaccines worldwide.

WHO failed in its efforts to help countries agree to a “pandemic treaty” — to improve preparedness and response to pandemics — before its annual meeting last month.

The project was shelved largely over disagreements about sharing of information about pathogens that cause epidemics and the high-tech tools used to fight them.

Negotiators will resume work on the treaty in hopes of clinching a deal by the next WHO annual meeting in 2025.

Thursday’s event in Paris also aims to help give a funding shot-in-the-arm to Gavi, the Vaccine Alliance, a public-private partnership that helps get needed vaccines to developing countries around the world.

Gavi says the project aims to make up to one billion dollars available over the next 10 years help boost Africa’s manufacturing base, to improve global vaccines markets and improve preparedness and response to pandemics and outbreaks like HIV, malaria, TB and Covid-19.

The Geneva-based alliance says the accelerator will inject funds into manufacturers in Africa once they hit supply and regulatory milestones, with an aim to use market forces to drive down prices and encourage investment upstream.

Officials say the project will explore issues like technology transfer — which has been resisted by some Western countries with powerful pharmaceutical companies — as well as the possible creation of a African medicines agency and tackling regulatory hurdles faced in Africa’s patchwork of legal systems.